A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt

Exclusion Criteria

• •1. Closed angle glaucoma (primary or secondary).
• •2. Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
• •3. Ocular medication of any kind within 30 days of base-line visit, with the exception of ocular hypotensive medications and/or lubricating drops for dry eye (which may be used throughout the study).
• •4. Any abnormality preventing reliable applanation tonometry of the treated eye.
• •5. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
• •6. Participation in any investigational study within the past 30 days.
• •7. Inability to perform reliable visual field testing.
• •8. Unwilling to sign the consent form approved by the Institutional Review Board (IRB) of the New York Eye and Ear Infirmary.
• •9. Self-reported poor compliance to treatment.
• •10. Reluctance to return for scheduled follow-up visits.
• •11. Patients not able to understand the nature of the study.